|
US4166452A
(en)
|
1976-05-03 |
1979-09-04 |
Generales Constantine D J Jr |
Apparatus for testing human responses to stimuli
|
|
US4256108A
(en)
|
1977-04-07 |
1981-03-17 |
Alza Corporation |
Microporous-semipermeable laminated osmotic system
|
|
US4265874A
(en)
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
|
US5914129A
(en)
*
|
1996-07-23 |
1999-06-22 |
Mauskop; Alexander |
Analgesic composition for treatment of migraine headaches
|
|
US6103260A
(en)
|
1997-07-17 |
2000-08-15 |
Mcneil-Ppc, Inc. |
Simethicone/anhydrous calcium phosphate compositions
|
|
WO2003080072A1
(en)
|
2002-03-18 |
2003-10-02 |
Cady Roger K |
Preemptive prophylaxis of migraine
|
|
DE10228326A1
(de)
*
|
2002-06-25 |
2004-01-22 |
Heribert Dr.med. Bohlen |
Verwendung von Macrolid- und/oder Tetracyclin-Verbindungen und/oder Gyrasehemmer enthaltenden Präparationen zur Prophylaxe und therapeutischen Behandlung von Migräne und Migräne-verwandten Erkrankungen
|
|
US20040076668A1
(en)
|
2002-07-03 |
2004-04-22 |
Pfizer Inc. |
Controlled-release pharmaceutical formulations
|
|
US7205293B2
(en)
|
2003-03-14 |
2007-04-17 |
Merck & Co., Inc. |
Benodiazepine spirohydantoin CGRP receptor antagonists
|
|
AU2004222378B2
(en)
|
2003-03-14 |
2008-08-14 |
Merck Sharp & Dohme Corp. |
Carboxamide spirohydantoin CGRP receptor antagonists
|
|
JO2355B1
(en)
|
2003-04-15 |
2006-12-12 |
ميرك شارب اند دوم كوربوريشن |
Hereditary calcitonin polypeptide receptor antagonists
|
|
CA2543458A1
(en)
|
2003-10-24 |
2005-05-12 |
Josef Rettenmaier & Soehne Gmbh & Co., Kg |
Process for co-spray drying agents with dry silicified mcc
|
|
US7390798B2
(en)
|
2004-09-13 |
2008-06-24 |
Merck & Co., Inc. |
Carboxamide spirolactam CGRP receptor antagonists
|
|
ATE464305T1
(de)
|
2004-09-13 |
2010-04-15 |
Merck Sharp & Dohme |
Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
|
|
DE102004063755A1
(de)
|
2004-12-29 |
2006-07-20 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
|
|
CA2599925A1
(en)
|
2005-03-14 |
2006-09-21 |
Merck & Co., Inc. |
Cgrp receptor antagonists
|
|
AU2007212197B2
(en)
|
2006-02-09 |
2012-12-13 |
Merck Sharp & Dohme Corp. |
Polymer formulations of CETP inhibitors
|
|
BRPI0711352A2
(pt)
|
2006-05-09 |
2011-09-27 |
Merck & Co Inc |
composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular
|
|
EP2161996B1
(en)
|
2007-06-05 |
2014-07-16 |
Merck Sharp & Dohme Corp. |
Heterocyclic carboxamide cgrp receptor antagonists
|
|
US8450327B2
(en)
|
2007-10-18 |
2013-05-28 |
Boehringer Ingelheim International Gmbh |
CGRP antagonists
|
|
WO2009065922A2
(de)
|
2007-11-22 |
2009-05-28 |
Boehringer Ingelheim International Gmbh |
Organische verbindungen
|
|
WO2009100090A1
(en)
|
2008-02-05 |
2009-08-13 |
Merck & Co., Inc. |
Prodrugs of cgrp receptor antagonist
|
|
US8044043B2
(en)
|
2008-04-11 |
2011-10-25 |
Bristol-Myers Squibb Company |
CGRP receptor antagonists
|
|
US20150023888A1
(en)
|
2008-09-05 |
2015-01-22 |
Map Pharmaceuticals, Inc. |
Method of Using Dihydroergotamine for Pre-emptive Treatment of Migraine
|
|
DK3222277T3
(da)
|
2009-03-31 |
2020-05-11 |
Ligand Pharm Inc |
Biphenylsulfonamidendothelin- og angiotensin II-receptorantagonist til behandling af glomerulosklerose og IgA-induceret nefropati
|
|
US8765763B2
(en)
|
2009-06-05 |
2014-07-01 |
Boehringer Ingelheim International Gmbh |
Substituted piperazines as CGRP antagonists
|
|
NZ605440A
(en)
|
2010-06-10 |
2014-05-30 |
Abbvie Bahamas Ltd |
Solid compositions comprising an hcv inhibitor
|
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
|
WO2012064911A1
(en)
|
2010-11-12 |
2012-05-18 |
Merck Sharp & Dohme Corp. |
Piperidinone carboxamide indane cgrp receptor antagonists
|
|
TWI522355B
(zh)
|
2010-11-12 |
2016-02-21 |
默沙東藥廠 |
六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
|
|
WO2012087777A1
(en)
|
2010-12-22 |
2012-06-28 |
Merck Sharp & Dohme Corp. |
Fused heterocyclic indane carboxamide cgrp receptor antagonists
|
|
US9067941B2
(en)
|
2010-12-22 |
2015-06-30 |
Merck Sharp & Dohme Corp. |
Fused heterocyclic azaindane carboxamide CGRP receptor antagonists
|
|
EP2654726A1
(en)
|
2011-03-08 |
2013-10-30 |
Zalicus Pharmaceuticals Ltd. |
Solid dispersion formulations and methods of use thereof
|
|
EP2685826B1
(en)
|
2011-03-18 |
2016-02-03 |
Merck Sharp & Dohme Corp. |
Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
|
|
US9109209B2
(en)
|
2011-09-08 |
2015-08-18 |
Codexis, Inc. |
Biocatalysts and methods for the synthesis of substituted lactams
|
|
US9487523B2
(en)
|
2012-03-14 |
2016-11-08 |
Merck Sharp & Dohme Corp. |
Process for making CGRP receptor antagonists
|
|
AU2013232191B2
(en)
|
2012-03-14 |
2017-03-30 |
Merck Sharp & Dohme Llc |
Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
|
|
CN104411295B
(zh)
|
2012-04-25 |
2017-10-10 |
伊诺威斯药物公司 |
敏感化组合物和使用方法
|
|
US9174989B2
(en)
|
2012-05-09 |
2015-11-03 |
Merck Sharp & Dohme Corp. |
Process for making CGRP receptor antagonists
|
|
US9227973B2
(en)
|
2012-05-09 |
2016-01-05 |
Merck Sharp & Dohme Corp. |
Pyridine CGRP receptor antagonists
|
|
EP2846799B1
(en)
|
2012-05-09 |
2017-11-15 |
Merck Sharp & Dohme Corp. |
Spirolactam cgrp receptor antagonists
|
|
WO2013169574A2
(en)
|
2012-05-09 |
2013-11-14 |
Merck Sharp & Dohme Corp. |
Aliphatic spirolactam cgrp receptor antagonists
|
|
NZ747040A
(en)
|
2013-03-15 |
2020-02-28 |
Tonix Pharmaceuticals Inc |
Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
|
|
RU2690006C2
(ru)
|
2013-09-16 |
2019-05-30 |
Мерк Шарп И Доум Корп. |
Композиции антагонистов рецепторов cgrp
|
|
US20160346198A1
(en)
|
2014-02-05 |
2016-12-01 |
Merck Sharp & Dohme Corp. |
Novel disintegration systems for pharmaceutical dosage forms
|
|
US12168004B2
(en)
|
2014-02-05 |
2024-12-17 |
Merck Sharp & Dohme Llc |
Treatment of migraine
|
|
EP3102564A4
(en)
|
2014-02-05 |
2017-10-18 |
Merck Sharp & Dohme Corp. |
Tablet formulation for cgrp-active compounds
|
|
US20240180883A1
(en)
|
2020-12-22 |
2024-06-06 |
Allergan Pharmaceuticals International Limited |
Treatment of migraine
|
|
EP3110427A4
(en)
|
2014-02-24 |
2018-05-30 |
Urigen Pharmaceuticals, Inc. |
Compositions of pentosan polysulfate salts for oral administration and methods of use
|
|
AU2015305696B2
(en)
|
2014-08-22 |
2019-08-29 |
Pharma& Schweiz Gmbh |
High dosage strength tablets of rucaparib
|
|
JP6673924B2
(ja)
|
2015-01-23 |
2020-03-25 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
|
|
EA201890578A1
(ru)
|
2015-09-24 |
2018-12-28 |
Тева Фармасьютикалз Интернэшнл Гмбх |
Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
|
|
US20180092899A1
(en)
|
2016-09-30 |
2018-04-05 |
Merck Sharp & Dohme Corp. |
Method of treating acute migraine with cgrp-active compound
|
|
CN110621343A
(zh)
|
2017-03-02 |
2019-12-27 |
贝丝以色列女执事医疗中心 |
选择对针对降钙素基因相关肽的抗体有反应的头痛患者
|
|
TWI754772B
(zh)
|
2017-09-06 |
2022-02-11 |
美商美國禮來大藥廠 |
用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
|
|
US20190135927A1
(en)
|
2017-09-29 |
2019-05-09 |
Bhl Patent Holdings, Llc |
Migraine, headache, chronic pain treatment, and prophylaxis options
|
|
AU2018362018A1
(en)
|
2017-11-06 |
2020-06-25 |
Auckland Uniservices Limited |
Peptide conjugate CGRP receptor antagonists and methods of preparation and uses thereof
|
|
US12383545B1
(en)
|
2018-06-08 |
2025-08-12 |
Allergan Pharmaceuticals International Limited |
Treatment of migraine
|
|
US20190374520A1
(en)
|
2018-06-08 |
2019-12-12 |
Allergan Pharmaceuticals International Limited |
Treatment of migraine
|
|
US20190374518A1
(en)
|
2018-06-08 |
2019-12-12 |
Allergan Pharmaceuticals International Limited |
Treatment of migraine
|
|
TWI826514B
(zh)
|
2018-09-04 |
2023-12-21 |
美商美國禮來大藥廠 |
用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
|
|
WO2020150703A1
(en)
|
2019-01-20 |
2020-07-23 |
Biohaven Pharmaceutical Holding Company Ltd. |
Cgrp antagonists for treating migraine breakthrough
|
|
CA3133912A1
(en)
|
2019-04-18 |
2020-10-22 |
Allergan Sales, Llc |
Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo
|
|
US20210121541A1
(en)
|
2019-07-05 |
2021-04-29 |
Allergan Pharmaceuticals International Limited |
CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
|
|
AU2020355233A1
(en)
|
2019-09-25 |
2022-05-19 |
Allergan Pharmaceuticals International Limited |
Combination therapy with CGRP antagonists
|
|
WO2021087210A1
(en)
*
|
2019-10-31 |
2021-05-06 |
R.P. Scherer Technologies, Llc |
Suppository capsule
|
|
EP4188375A4
(en)
|
2020-07-29 |
2024-07-24 |
Allergan Pharmaceuticals International Limited |
MIGRAINE TREATMENT
|
|
AU2021409718A1
(en)
|
2020-12-22 |
2023-07-13 |
Allergan Pharmaceuticals International Limited |
Treatment of migraine
|
|
MX2024003952A
(es)
|
2021-09-27 |
2024-05-27 |
Allergan Pharmaceuticals Int Ltd |
Combinación que comprende atogepant para tratar la migraña.
|
|
AU2023231645A1
(en)
|
2022-03-09 |
2024-09-12 |
Allergan Pharmaceuticals International Limited |
Preventive treatment of migraine
|
|
WO2024081718A1
(en)
|
2022-10-11 |
2024-04-18 |
Allergan Pharmaceuticals International Limited |
Cgrp receptor antagonist for the treatment of migraine
|